<SEC-DOCUMENT>0001104659-21-040026.txt : 20210323
<SEC-HEADER>0001104659-21-040026.hdr.sgml : 20210323
<ACCEPTANCE-DATETIME>20210323080010
ACCESSION NUMBER:		0001104659-21-040026
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210323
FILED AS OF DATE:		20210323
DATE AS OF CHANGE:		20210323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		21763182

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2110545d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE
13a-16 OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE
ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of March, 2021</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified
in Its Charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD>
    <TD STYLE="width: 16%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation&nbsp;S&#45;T&nbsp;Rule&nbsp;101(b)(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation&nbsp;S&#45;T&nbsp;Rule&nbsp;101(b)(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2021, CureVac N.V. (the &#8220;Company&#8221;)
issued a press release announcing the publication of preclinical data demonstrating that the Company&#8217;s COVID-19 vaccine candidate,
CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2
B1 lineage (BavPat1) in a transgenic mouse model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Form 6-K (including
Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange
Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 53%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 23%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="vertical-align: top; width: 23%; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 88%"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated March 23, 2021.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2110545d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Exhibit
99.1&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><IMG SRC="tm2110545_ex99-1img01.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CureVac&rsquo;s COVID-19 Vaccine
Candidate, CVnCoV, Demonstrates Protection Against<BR>
SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>First
                                         challenge infection study in preclinical mouse model to provide evidence for protection
                                         against SARS-CoV-2 variant</I></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>CVnCoV
                                         induces robust antibody titers with virus variant neutralizing capacity in immunized
                                         animals</I></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Full
                                         protection of immunized mice from infection and mortality during variant challenge infection</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>T&Uuml;BINGEN,
Germany/ BOSTON, USA &ndash; March 23, 2021 </B></FONT><B><FONT STYLE="font-size: 10pt">&ndash;</FONT></B><FONT STYLE="font-size: 10pt">
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger
ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate,
CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 (also referred to as the &ldquo;South
African&rdquo; variant) and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model. Consistent with
available variant studies, the neutralization capacity of robust antibody titers was shown to be impacted by the B.1.351 variant
compared to the original strain. However, vaccinated animals were fully protected from lethal challenge infections with both strains.
The full manuscript of the preclinical data is available on the <U>bioRxiv</U> preprint server.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;Emergence of new SARS-CoV-2
strains, which exhibit the potential to escape an existing SARS-CoV-2 immunity, pose an increasing risk to the progress of current
global immunization efforts,&rdquo; said Igor Splawski, Chief Scientific Officer of CureVac. &ldquo;To our knowledge, this is
the first challenge study in a human ACE2 transgenic mouse model of severe disease that shows complete protection against one
of the most threatening virus variants.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Within the study, transgenic
mice expressing the human ACE2 receptor, the receptor through which SARS-CoV-2 enters human cells, were immunized with 8&micro;g
of CVnCoV per dose, following a two-dose vaccination schedule at day 0 and day 28. Vaccination resulted in robust antibody responses
and complete protection (100% survival) against the original SARS-CoV-2 strain and also B.1.351 (variant strain first identified
in South Africa) challenge infections. CVnCoV vaccination efficiently blocked viral replication of B.1.351 in the lower respiratory
tract and brain, and reduced viral replication in the upper respiratory tract in vaccinated and challenged animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About
CVnCoV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac
began development of its mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen first for clinical
development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein
of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a clinical trials of CVnCoV began in June
and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated
across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality
of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19
infection. In December 2020, CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12&micro;g dose of CVnCoV. In February
2021, CureVac </FONT><FONT STYLE="font-size: 10pt">initiated a rolling submission with the European Medicines Agency (EMA) for
CVnCoV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac
has entered into several strategic partnerships for the further development, production and commercialization of CVnCoV. The company
entered into a collaboration agreement with Bayer in January 2021 with regards to CureVac&acute;s current vaccine candidate CVnCoV.
In February 2021, CureVac and the British pharmaceutical company GlaxoSmithKline (GSK) agreed to jointly develop next-generation
multi-valent mRNA vaccines against COVID-19. The development of new vaccine candidates is strengthened by a partnership with the
</FONT><FONT STYLE="font-size: 10pt">UK Government and its Vaccines Taskforce, which CureVac also entered in February 2021. GSK
will also potentially contribute to this collaboration. Clinical trial and commercial material is provided by the company&rsquo;s
substantial production capacities for mRNA vaccines at its headquarters in T&uuml;bingen, supported by the current expansion of
manufacturing capacities in Europe, allowing broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
CureVac</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">CureVac
is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in
developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology
is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of
fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across
the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its
initial public offering on the New York Nasdaq in August 2020. It is headquartered in T&uuml;bingen, Germany, and employs more
than 600 people at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information can be found at <U>www.curevac.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CureVac Media Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Thorsten Sch&uuml;ller, Vice
President Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CureVac, T&uuml;bingen, Germany</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">T: +49 7071 9883-1577</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>thorsten.schueller@curevac.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CureVac Investor Relations
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dr. Sarah Fakih, Vice President
Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CureVac, T&uuml;bingen, Germany</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">T: +49 7071 9883-1298</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">M: +49 160 90 496949</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>sarah.fakih@curevac.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains statements that constitute &ldquo;forward looking statements&rdquo; as that term is defined in the United
States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs,
plans, objectives, assumptions or projections of CureVac (the &ldquo;company&rdquo;) regarding future events or future results,
in contrast with statements that reflect historical facts. Examples include discussion of the </FONT><FONT STYLE="font-size: 10pt">potential
efficacy of the company&rsquo;s vaccine and treatment candidates and the company&rsquo;s strategies, financing plans, growth opportunities
and market growth. In some cases, you can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo;
or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements
are based on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance
on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including
negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain
funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of
regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture
any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing
competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s business
and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors.
Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on
such statements. Many of these risks are outside of the company&rsquo;s control and could cause its actual results to differ materially
from those it thought would occur. The forward-looking statements included in this press release are made only as of the date
hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please reference the company&rsquo;s reports and documents filed with the U.S. Securities and Exchange Commission
(SEC). You may get these documents by visiting EDGAR on the SEC website at </FONT><FONT STYLE="font-size: 10pt"><U>www.sec.gov</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2110545_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110545_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U )@# 2(  A$! Q$!_\0
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M^AR?0<G%%9U[X2^VWIG-V '#!SY9W*'7;(%YQA@3U!QGBB@#IJ*** "BBB@
MHHHH **** "BBB@ HHHH **** *$=BT6O7%\)ODGMXXVAV_Q(SG=GW#8Q[5?
EHHH Q-6\V/Q#H$L<I57FF@D3'WU,3-^C1J:VZ** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
